Is Amylin legal in the United Kingdom?

Co-released with insulin from the same beta cell, and the parent ligand of cagrilintide and CagriSema. Native human amylin clumps into amyloid, which is why it can never be a drug.

Amylin is secreted alongside insulin from the pancreatic beta cell in a roughly fixed ratio, which has a consequence people miss: someone with type 1 diabetes is deficient in two hormones, not one. It slows gastric emptying, suppresses glucagon after a meal, and produces satiation through the area postrema in the brainstem.

Mechanism: Acts at amylin receptors, which are not dedicated receptors at all but the calcitonin receptor in complex with a receptor activity-modifying protein. RAMP1, RAMP2 or RAMP3 give AMY1, AMY2 and AMY3 respectively, and that accessory-protein mechanism is why amylin pharmacology overlaps with calcitonin.

Regulatory history: Native amylin is not a drug. Its approved analogue pramlintide (Symlin) is listed as Discontinued in Drugs@FDA as of September 2026. Cagrilintide is investigational, in phase 3 combined with semaglutide.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Amylin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.